Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

By R. Rampling, Garth Cruickshank, V. Papanastassiou, James A. R. Nicoll, Donald M. Hadley, D. Brennan, Russell D. Petty, A. Maclean, J. Harland, EA McKie and 2 more. Gene Therapy, 2000

615 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/76b84bd01560b57b46e7cc333a8b9bfa8bf78d49

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. María García
2. M. Esteban
3. Susana Guerra
4. I. Ventoso
5. J. Gil
6. E. Domingo
7. C. Rivas
8. B. Roizman

Citations in the corpus

• Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action (2006, background): “protein, for specific regression of malignant glioma (241, 291).”
• Herpes simplex viruses: is a vaccine tenable? (2002, background): “In this trial, a total of nine patients were evaluated at one of three doses of virus, beginning at 1 × 103 and escalating by a factor of 10 to 1 × 105 (53).”